|
|
News Breaks | | | | February 21, 2013 | | 08:54 EDT |  | ACHN | Achillion shares should be bought on any weakness, says JMP Securities
After Achillion announced a financing deal that JMP Securities believes may cause the stock to retreat, the firm thinks the company is poised to report "transformative data" this year. The firm thinks the company's HCV treatments have no safety risks, and it reiterates a $15 price target and Outperform rating on the shares. | |
|
News For ACHN From The Last 14 Days Check below for free stories on ACHN the last two weeks. |
|
|
| May 16, 2013 | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
 Subscribe for More Information | | | May 15, 2013 | | 06:06 EDT |  | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | |
|
|
|
|
|
|
